Slide 1: Ansell FY25 Full Year Results
ANSELL FY25 FULL YEAR RESULTS 25 August 2025
Slide 2: Disclaimer and Non-IFRS Measures
FULL YEAR RESULTS FY25 Disclaimer and Non-IFRS Measures The following presentation has been prepared by Ansell Limited (Ansell or the Company) for information purposes only. The information contained in this presentation is a summary only and does not purport to be complete. It should be read in con
Slide 3: Contents and Key Highlights
FULL YEAR RESULTS FY25 Contents 1 2 3 4 5 Topics Performance Key Growth Drivers Financial FY26 Q&A Overview & Sustainability Results Outlook Update Successful delivery KBU results ahead of Strong sales growth Pricing to offset higher against all FY25 business case, and margin US tariffs in full Key
Slide 4: 1. Performance Overview
1. Performance Overview 4
Slide 5: Strong Delivery Against Key Performance Objectives
FULL YEAR RESULTS FY25 Strong Delivery Against Key Performance Objectives Our Previously Stated Goals FY25 Performance Summary Financials Organic CC2 sales growth in 9.4% growth2 in Healthcare, 5.6% in Industrial Organic ($m)1 FY25 %∆ Industrial and Healthcare Healthcare recovery from destocking
Slide 6: Record Sales & EBIT Margin In Industrial
FULL YEAR RESULTS FY25 Record Sales & EBIT Margin In Industrial Industrial Segment – Summary Financials Sales Performance ($m) FY24 FY25 %∆ Org CC1 % ∆ • Organic CC1 sales growth despite subdued end market conditions, Sales 785.1 898.6 14.4% 5.6% primarily driven by new products EBIT 129.3 155.5 20.
Slide 7: Healthcare Rebound Post Destocking
FULL YEAR RESULTS FY25 Healthcare Rebound Post Destocking Healthcare Segment – Summary Financials Sales Performance ($m) FY24 FY25 %∆ Org CC1 % ∆ • Organic CC1 sales growth included higher volumes across all SBU’s Sales 834.2 1,104.7 32.4% 9.4% • Destocking recovery contributed to strong rates of gr
Slide 8: 2. Key Growth Drivers & Sustainability Update
2. Key Growth Drivers & Sustainability Update 8
Slide 9: Clear Progress Made To Strengthen Our Business
FULL YEAR RESULTS FY25 Clear Progress Made To Strengthen Our Business Differentiated Customer Solutions Aligned Productivity-Enhancing Investments To To Industry Trends Enable Growth & Mitigate Cost Inflation • Double-digit growth in Industrial new products • Success with APIP • Significant increase
Slide 10: KBU Performance Ahead Of Business Case, Integration Complete, Synergies Target Upgraded
FULL YEAR RESULTS FY25 KBU Performance Ahead Of Business Case, Integration Complete, Synergies Target Upgraded FY25 Performance Integration Update Synergies Target Sales of $274.2m Integration completed with a seamless FY27 annualised net pre-tax cost • Double-digit growth in KimtechTM customer expe
Slide 11: Leveraging Market-Leading KBU Brands To Enhance The Growth Potential Of Our Combined Portfolio
FULL YEAR RESULTS FY25 Leveraging Market-Leading KBU Brands To Enhance The Growth Potential Of Our Combined Portfolio Ansell’s portfolio of brands, synonymous with quality and performance, has the highest levels of awareness in protective gloves and clothing1 Industrial Segment: Key Product Brands H
Slide 12: APIP: On Track To Achieve Savings Goals, Focus Turns To ERP System Upgrades
FULL YEAR RESULTS FY25 APIP: On Track To Achieve Savings Goals, Focus Turns To ERP System Upgrades Commencing in FY26 Work Stream FY25 Progress Update Summary Financials Organisation Changes completed in FY24 Simplify & Streamline Reorganised customer units benefiting from enhanced focus and API
Slide 13: APIP: Commercial ERP System Upgrades To Complete Multi-Year Digital Transformation
FULL YEAR RESULTS FY25 APIP: Commercial ERP System Upgrades To Complete Multi-Year Digital Transformation Ansell ERP Journey Pre FY26 FY26-28 Post FY28 Outside of APIP Scope Focus of APIP IT Workstream Unifying Manufacturing ERP Systems Unifying Customer-Facing ERP Systems End State 16 ERP systems i
Slide 14: Delivering Against Sustainability Objectives, Net Zero Target Now Includes Scope 3 Emissions
FULL YEAR RESULTS FY25 Delivering Against Sustainability Objectives, Net Zero Target Now Includes Scope 3 Emissions People We focus on enhancing the health and well-being of our employees, creating decent and inclusive work environments and reducing Planet We aim to achieve a zero-carbon future by r
Slide 15: 3. Financial Results
3. Financial Results 15
Slide 16: Strong Organic CC Sales & Earnings Growth
FULL YEAR RESULTS FY25 Strong Organic CC 1 Sales & Earnings Growth P&L Summary Key Comments ($m) FY24 FY25 %∆ Org CC1 % ∆ • Best Organic CC1 sales growth in over a decade, excluding Sales 1,619.3 2,003.3 23.7% 7.7% pandemic-assisted year of FY21 Cost of Goods Sold (994.5) (1,178.3) 18.5% 6.2% • GPAD
Slide 17: Strengthening Balance Sheet, Improvement in ROCE
FULL YEAR RESULTS FY25 Strengthening Balance Sheet, Improvement in ROCE Balance Sheet Summary Key Comments ($m) Jun-24 Jun-25 • Strong balance sheet with Moody’s Baa2 investment grade Fixed Assets 349.3 377.2 rating Intangibles 1,054.8 1,655.5 • Inventory at Jun-25 included $46m from the KBU busines
Slide 18: Good Cash Conversion
FULL YEAR RESULTS FY25 Good Cash Conversion 1 115.2 (20.1) (95.5) (68.0) (39.2) (45.4) FY25 258.4 278.1 (63.7) ($m) 0.0 (13.2) (635.1) 105.4 ((606.6) Statutory Working Other Net Receipts Lease Net Capex Net Interest Taxes Operating Dividend Buyback FX Net Debt Acquisitions NIBD EBITDA² Capital Payme
Slide 19: Significant Liquidity & Balance Sheet Capacity To Fund Growth Investments & Capital Management
FULL YEAR RESULTS FY25 Significant Liquidity & Balance Sheet Capacity To Fund Growth Investments & Capital Management Net Debt Summary Key Comments ($m) Jun-24 Jun-25 • KBU acquisition drove increase in Net Debt versus 30-Jun-24 Interest-Bearing Debt 766.3 698.9 – Excluding consideration for the KBU
Slide 20: Opportunities For Improved Financial Performance & Value Creation
FULL YEAR RESULTS FY25 Opportunities For Improved Financial Performance & Value Creation Accelerated Sales Growth Margin Improvement Cash Flow Conversion • Benefits from market-leading brand • Continuous focus on manufacturing • Drive faster inventory turnover while positioning productivity maintain
Slide 21: 4. FY26 Outlook
Ansell 4. FY26 Outlook
Slide 22: Well Positioned To Adapt To Higher US Tariffs
FULL YEAR RESULTS FY25 Well Positioned To Adapt To Higher US Tariffs Our products are essential Glove industry We have a diversified, We have a demonstrated and differentiated manufacturing is flexible manufacturing & history of passing through concentrated in Asia sourcing network cost increases Ou
Slide 23: FY26 Adjusted EPS Guidance Range US133¢ to US145¢, Up From US126.1¢ In FY25
FULL YEAR RESULTS FY25 FY26 Adjusted EPS 1 Guidance Range US133¢ to US145¢, Up From US126.1¢ In FY25 What We Expect To See Guidance Assumptions • Constant currency2 sales growth from both higher volumes and tariff-related pricing • Solid healthcare demand – Pricing to offset higher tariffs in full,
Slide 24: FY26 Actions Reinforcing Our Investment Proposition
FULL YEAR RESULTS FY25 FY26 Actions Reinforcing Our Investment Proposition Leading Positions In Comprehensive Service Solutions Resilient Supply Sustainability Strong Cash Growing Markets Product Portfolio Valued By Customers Chain Leadership Flows Pivoting focus to Further “new to Launching next-ge
Slide 25: 5. Q&A
5. Q&A 25
Slide 26: Appendix
Appendix 26
Slide 27: Sales & EBIT Impact Of FX Movements
FULL YEAR RESULTS FY25 Sales & EBIT Impact Of FX Movements FX Impact ($m) Key Comments Sales EBIT FY25 vs FY24 • Net reduction in Sales and EBIT, largest adverse movements were in the BRL, MYR and THB FX Rate Movements (5.4) (11.4) • FX momentum shifted in the final quarter of the year as key sales
Slide 28: Input Costs Summary
FULL YEAR RESULTS FY25 Input Costs Summary FY25 Input Cost Trends • NBR and NRL costs higher versus FY24, though softened in H2. Majority of synthetics and yarns stable • Employee cost inflation persists in key manufacturing locations, including additional social compliance costs. Continued focus on
Slide 29: Capex Summary
FULL YEAR RESULTS FY25 Capex Summary FY25 Capex Summary • Total FY25 capex of $69.3m included $25.8m towards the greenfield Greenfield India Surgical Facility India Surgical facility • Other spend included sustainability projects, site improvements and productivity initiatives • FY26 capex expected
Slide 30: Organic Constant Currency
FULL YEAR RESULTS FY25 Organic Constant Currency Constant Currency Restated Prior Period ($m) • The presentation of constant currency information is designed to Industrial Healthcare Corporate Group facilitate comparability of reported earnings by restating the prior Prior Period Sales period’s resu
Slide 31: Segment History
FULL YEAR RESULTS FY25 Segment History ($m) FY141 FY151 FY161 FY171 FY181 FY191 FY201 FY211 FY22 FY23 FY24 FY25 Ansell Sales 1,377.5 1,428.1 1,352.8 1,374.5 1,489.8 1,499.0 1,613.7 2,026.9 1,952.1 1,655.1 1,619.3 2,003.3 2,3,4,5,6 EBIT 175.5 210.9 188.2 178.4 193.43 200.9 216.7 338.0 245.1 206.3 195
Slide 32: Ansell Fact Sheet
FULL YEAR RESULTS FY25 Ansell Fact Sheet Key Figures Key FY26 Assumptions • Booked Tax Losses at 30 June 2025: $24.0m (Australia $16.4m) • Foreign exchange exposures by currency: Revenue currencies: USD 56%, EUR 25%, CAD 4%, GBP 4%, CNY • Unbooked Tax Losses at 30 June 2025: $13.8m (Tax-Effected) 3%
Slide 33: Glossary
FULL YEAR RESULTS FY25 Glossary AI – Artificial Intelligence ERP – Enterprise Resource Planning NIBD – Net Interest-Bearing Debt APIP – Accelerated Productivity Investment Program EUR – Euro NRL – Natural Rubber Latex AUD – Australian Dollar FX – Foreign Exchange ROCE – Return On Capital Employed BR
Slide 34: Ansell
Ansell Lead the world to a safer future. www.ansell.com